Li Lab: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
(71 intermediate revisions by 2 users not shown)
Line 6: Line 6:
<div style="float:left;margin-left:0.3em;margin-right:0.7em">
<div style="float:left;margin-left:0.3em;margin-right:0.7em">


== '''Computational Epigenomics and Transcriptomics Lab (PI: Wei Li)''' ==  
== '''Computational Cancer Epigenomics and Transcriptomics (PI: Wei Li)''' ==  


[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
Line 15: Line 15:


==Recent News==
==Recent News==
. 02/2014: Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to '''Cell Stem Cell'''.
. 11/2015: We received a new '''NIH/NCI R01''' grant (scored at 5%ile) to study 3`UTR alternations in human cancers.


. 01/2014: Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to '''Genome Biology'''.
. 09/2015: Welcome our new Research Associate (and potential Graduate Student) YanBing Cheng.


. 01/2014: Our collaborative work on Breast Cancer Epigenetics is accepted to '''Science Translational Medicine'''.
. 08/2015: Kaifu's Cancer Big-data analysis paper is published in '''Nature Genetics'''. This work links broad H3K4me3 to pan-cancer tumor suppressors. See reports in Nature Editor’s [http://blogs.nature.com/freeassociation/2015/08/methylation-marks-tumor-suppressors.html Blog], [http://cancerdiscovery.aacrjournals.org/content/early/2015/09/01/2159-8290.CD-RW2015-166.abstract Cancer Discovery], [http://www.ebiotrade.com/newsf/2015-8/2015825165005119.htm ebiotrade.com] (in Chinese), [http://fromthelabs.bcm.edu/2015/10/15/novel-epigenetic-signature-for-tumor-suppressors-in-normal-cells-found/ BCM news] and [http://cancer.osu.edu/news-and-media/news/studies-suggest-new-ways-to-inhibit-oncogenes-enhance-tumor-suppressor-activity OSU news]; and an error we found in a [http://www.cell.com/cell/fulltext/S0092-8674(15)01407-5 Cell paper].


. 01/2014Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to '''Nature'''. This work links transcription elongation to tumor suppression.
. 07/2015Wei will become a regular member of the '''NIH GCAT''' (Genomics, Computational Biology and Technology) study section.


. 12/2013: Kaifu's aging nucleosome paper is accepted to ''' Genes & Development'''  
. 06/2015: Kaifu will start his '''tenure-track faculty''' position at Cornell University & Methodist Hospital. Congratulations!


. 12/2013: We received a 5-year NIH/NHGRI '''R01''' grant (scored at 6 percentile in its first submission) to study DNA Methylation
. 03/2015: Kaifu's MeCP2 mCH binding paper (w/ Zoghbi lab) is accepted to '''PNAS'''.


. 11/2013: Wei will serve on the Editorial Board of '''Molecular Endocrinology'''
. 3/2015: We received a NEW '''CPRIT''' grant. 


. 09/2013:  Deqiang's DNA methylation Canyon paper is accepted to '''Nature Genetics'''.
. 01/2015:  Deqiang, HJ and Ben's HSC novel noncoding RNA paper is accepted to '''Cell Stem Cell''' -- the 100th paper we published.


. 09/2013Xueqiu's bisulfite sequencing quality control paper (BSeQC) is accepted to '''Bioinformatics'''.
. 12/2014Zheng Xia is awarded a '''Keck fellowship''' in Computational Cancer Biology.


. 08/2013Kadir's p53 paper is accepted to '''Nucleic Acids Research'''
. 11/2014Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in '''Nature Communications'''.


. 06/2013Zheng's TCGA RNA-seq bioinformatics paper is under review in '''Nature Biotechnology'''.
. 09/2014Liguo's ChIP-exo methodology paper (MACE) is accepted to '''Nucleic Acids Research'''.  MACE is recommended by Active Motif as the software solution for the company's new [https://www.activemotif.com/catalog/1050/chip-exo ChIP-exo kit and service].


. 01/2013: Zheng's 3'UTR paper is in revision in '''Nature'''. Fingers Crossed!
. 09/2014: Deqiang will start his '''tenure-track assistant professor''' position. Job well done.


. 01/2013[http://www.bcm.edu/news/item.cfm?newsID=6723 BCM News] and  [http://epigenie.com/danpos-reveals-dynamic-nucleosomes Epigenie Headline] about our recent work on nucleosome dynamics.
. 09/2014Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to '''Molecular Cancer Research '''.  


. 12/2012Liguo and HJ's CPAT RNA coding potential prediction paper is accepted to '''Nucleic Acids Research'''.
. 09/2014Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to '''Cell'''.


. 11/2012Kaifu's nucleosome methodology paper DANPOS is accepted to '''Genome Research'''.
. 08/2014:  '''Three Collaborative CPRIT grants''' are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.


. 10/2012Kaifu's promoter nucleosome paper is accepted to '''Genome Research'''.
. 06/2014Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to '''Cell Stem Cell '''.  


. 09/2012A '''NIH R01 grant''' was funded. We will work with Dr. Issa at Temple Univ. to understand DNA methylation in Cancer.
. 06/2014Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to '''Molecular Cell '''.  


. 08/2012: A mouse ES nucleosome paper from Kaestner lab at Upenn is accepted to '''Cell'''. Kaifu and Wei used DANPOS to analyze the data and were listed as co-authors.
. 02/2014: Zheng's brain tumor 3'UTR regulator paper is accepted to '''Nature'''. This paper was initially rejected after review twice. We appealed twice with success and finally made it in the 3rd submission.


. 08/2011: Dr. Benjamin Rodriguez will join us as a '''Postdoc Associate'''. Ben has PhD in Integrated Biomedical Science from the Ohio State Univ. Welcome!
. 02/2014: Welcome our new postdoc Jianzhong Su and graduate student Xueqiu Lin.


. 08/2012A '''Mazzone Award ''' is funded. We will work with Dr. Balk at Harvard Medical School to understand the molecular features of aggressive prostate cancer.
. 02/2014Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to '''Cell Stem Cell'''.
. 06/2012: Liguo's RNA-seq Quality Control paper is accepted to '''Bioinformatics'''.


. 06/2012A '''NIH R01 grant''' is funded. We will work with Dr. Goodell at BCM to understand DNA methylation in Hematopoietic Stem Cell.
. 01/2014Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to '''Genome Biology'''.


. 04/2012A '''NIH R01 grant''' is funded. We will work with Dr. Dent at MD Anderson to define USP22 functions during mammalian development.
. 01/2014Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to '''Nature'''. This work links transcription elongation to tumor suppression.


. 04/2012:  Dr.Dean Tang's prostate cancer stem cell paper is accepted in '''Cell Stem Cell'''. Wei is a co-author.


. 02/2012:  Yuanxin's epigenetic paper with Katrin Chua lab at Stanford is accepted to '''Nature'''. Two years of hard work finally paid off!
. 02/2012:  Liguo Wang is offered a '''tenure-track Assistant Professor''' position at Mayo Clinic. Congratulations!
. 02/2012:  Justin Park will join us as a Postdoc Associate. Justin will graduate in May with a PhD in Computer Science from Rice University. Welcome!


[[Image:Banner.jpg‎‎]]
[[Image:Banner.jpg‎‎]]
Line 91: Line 83:
<div style="border-bottom: 1px dashed #9999CC;">
<div style="border-bottom: 1px dashed #9999CC;">


Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have published more than 50 peer-reviewed papers in high profile journals, such as Nature, Cell, Nature Genetics, Molecular Cell, Genome Research, Genome Biology, Genes and Development, Nucleic Acids Research, Cancer Research, PNAS and Bioinformatics.
Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have  
* '''Published''' more than 75 peer-reviewed papers through solid methodology development and extensive collaboration research, including 28 in '''Nature, Science and Cell''' series.
 
* '''Been well-funded''' by NIH and Texas CPRIT with total external funding >$1.3 million per year. Dr Li is the PI on the following 4 major grants: NIH R01HG007538 (2013-2018) and R01CA193466 (2015-2020); CPRIT RP110471-C3 (2011-2016) and RP150292 (2015-2018).
* '''Mentored''' the first 3 postdoc trainees to start their tenure track faculty positions in prestigious research institutions in the US.


We developed a number of widely used algorithms to analyze next generation sequencing data from Chromatin Factor ChIP-seq (MACS, MACE, DyChIPS), DNA Methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), Nucleosome Positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1000 citations since 2008.  
We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1900 citations since 2008.  


In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.
In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.


* Chromatin Factors: ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation.
* '''Chromatin Factors''': ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..


* DNA Methylation: Dnmt3a in HSC differentiation, DNA methylation Canyon, HSC aging.  
* '''DNA Methylation''': DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.  


* Nucleosome Organization: fragile nucleosome in gene poising, promoter nucleosome with Tup1, nucleosome dynamics in ES differentiation, global nucleosome loss in aging.
* '''Nucleosome Organization''': Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.


* Transcriptome: chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and their master regulators.
* '''Transcriptome''': chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


   
   

Revision as of 15:41, 20 November 2015

Home        People        Publications        Collaborations        Software        Positions        Contact       


Recent News

. 11/2015: We received a new NIH/NCI R01 grant (scored at 5%ile) to study 3`UTR alternations in human cancers.

. 09/2015: Welcome our new Research Associate (and potential Graduate Student) YanBing Cheng.

. 08/2015: Kaifu's Cancer Big-data analysis paper is published in Nature Genetics. This work links broad H3K4me3 to pan-cancer tumor suppressors. See reports in Nature Editor’s Blog, Cancer Discovery, ebiotrade.com (in Chinese), BCM news and OSU news; and an error we found in a Cell paper.

. 07/2015: Wei will become a regular member of the NIH GCAT (Genomics, Computational Biology and Technology) study section.

. 06/2015: Kaifu will start his tenure-track faculty position at Cornell University & Methodist Hospital. Congratulations!

. 03/2015: Kaifu's MeCP2 mCH binding paper (w/ Zoghbi lab) is accepted to PNAS.

. 3/2015: We received a NEW CPRIT grant.

. 01/2015: Deqiang, HJ and Ben's HSC novel noncoding RNA paper is accepted to Cell Stem Cell -- the 100th paper we published.

. 12/2014: Zheng Xia is awarded a Keck fellowship in Computational Cancer Biology.

. 11/2014: Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in Nature Communications.

. 09/2014: Liguo's ChIP-exo methodology paper (MACE) is accepted to Nucleic Acids Research. MACE is recommended by Active Motif as the software solution for the company's new ChIP-exo kit and service.

. 09/2014: Deqiang will start his tenure-track assistant professor position. Job well done.

. 09/2014: Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to Molecular Cancer Research .

. 09/2014: Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to Cell.

. 08/2014: Three Collaborative CPRIT grants are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.

. 06/2014: Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to Cell Stem Cell .

. 06/2014: Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to Molecular Cell .

. 02/2014: Zheng's brain tumor 3'UTR regulator paper is accepted to Nature. This paper was initially rejected after review twice. We appealed twice with success and finally made it in the 3rd submission.

. 02/2014: Welcome our new postdoc Jianzhong Su and graduate student Xueqiu Lin.

. 02/2014: Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to Cell Stem Cell.

. 01/2014: Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to Genome Biology.

. 01/2014: Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to Nature. This work links transcription elongation to tumor suppression.


News Archive




Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have

  • Published more than 75 peer-reviewed papers through solid methodology development and extensive collaboration research, including 28 in Nature, Science and Cell series.
  • Been well-funded by NIH and Texas CPRIT with total external funding >$1.3 million per year. Dr Li is the PI on the following 4 major grants: NIH R01HG007538 (2013-2018) and R01CA193466 (2015-2020); CPRIT RP110471-C3 (2011-2016) and RP150292 (2015-2018).
  • Mentored the first 3 postdoc trainees to start their tenure track faculty positions in prestigious research institutions in the US.

We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1900 citations since 2008.

In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.

  • Chromatin Factors: ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..
  • DNA Methylation: DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.
  • Nucleosome Organization: Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.
  • Transcriptome: chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


Lab Intranet openwetware


<html> <script type="text/javascript">

 var _gaq = _gaq || [];
 _gaq.push(['_setAccount', 'UA-5924762-2']);
 _gaq.push(['_trackPageview']);
 (function() {
   var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
   ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
   var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
 })();

</script> </html>